Medical device company Boston Scientific (NYSE: BSX) announced better-than-expected revenue in Q1 CY2026, with sales up 11.6% year on year to $5.20 billion. On the other hand, next quarter’s revenue guidance of $5.39 billion was less impressive, coming in 2.9% below analysts’ estimates. Its non-GAAP profit of $0.80 per share was 1.6% above analysts’ consensus estimates.

Is now the time to buy BSX? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Boston Scientific’s first quarter saw a strong positive market reaction, underpinned by solid organic sales growth and improved operating margins. Management attributed the quarterly outperformance to robust demand in neuromodulation, interventional cardiology, and continued adoption of newer platforms such as FARAPULSE and WATCHMAN FLX Pro. CEO Michael Mahoney noted that five of the company’s eight business units posted double-digit growth in the U.S., with Asia Pacific also delivering significant operational gains. However, the quarter was not without challenges, as certain product lines, including urology and standalone WATCHMAN procedures, underperformed due to operational and market-specific issues.

Looking forward, Boston Scientific’s management anticipates a more difficult operating environment for the remainder of the year, leading to reduced revenue and adjusted EPS guidance. Mahoney pointed to ongoing headwinds in electrophysiology (EP), urology, and WATCHMAN, citing increased competition and evolving practice patterns. He emphasized, “We believe our updated guidance appropriately reflects the unanticipated headwinds, and we remain highly focused on executing our full-year 2026 guidance.” The company expects the effects of these pressures to moderate later in the year as new product launches and commercial strategies gain traction, but acknowledged that reaching previous long-term growth targets will be a challenge in the near term.

Key Insights from Management’s Remarks

Management identified shifting product demand, competitive pressures, and operational disruptions as the main forces shaping both recent results and the revised outlook.

• WATCHMAN volume shifts: The company experienced a decline in standalone WATCHMAN procedures, offset by growing demand for combined (concomitant) procedures. Management cited hospital workflow changes and reimbursement dynamics as key contributors to this shift.
• Electrophysiology (EP) competition: Boston Scientific maintained its leadership in pulsed field ablation (PFA), but acknowledged increased competitive pressure from large peers like Medtronic, J&J, and Abbott. This led to higher-than-expected share erosion in the U.S. EP business, prompting a downward revision to growth expectations.
• Urology commercial disruption: The urology segment underperformed due to both product gaps in stone management and significant turnover in the sales and clinical field teams. Management responded by hiring and training nearly 100 new representatives, aiming for gradual recovery throughout the year.
• Asia Pacific and interventional oncology strength: Double-digit growth in Asia Pacific was driven by strong results in Japan and China, particularly for imaging technologies and cancer therapy products. The company also highlighted the launch of new mapping systems and expanded indications in these regions.
• Operational efficiency initiatives: To offset margin headwinds from product mix and tariffs, Boston Scientific implemented stricter spending controls and accelerated organizational efficiency efforts, including shared services and automation projects. These efforts are aimed at protecting profitability despite lower growth in some high-margin products.

Drivers of Future Performance

Management expects revenue growth to slow as a result of market-specific headwinds, competitive dynamics, and internal execution challenges, while focusing on operational efficiency to support margins.

• Product launches and pipeline: Several key launches in 2026 and 2027, including next-generation FARAPULSE and FANAFLEX in electrophysiology, are expected to support growth, but their impact will be more pronounced in future years rather than immediately offsetting current headwinds.
• Commercial and operational investments: Management is prioritizing investments in targeted commercial activities, especially for WATCHMAN and urology, and streamlining R&D to focus on the highest-impact projects. These initiatives are intended to restore growth in underperforming segments and improve overall execution.
• Margin management amid lower mix benefit: With high-margin products like U.S. EP and WATCHMAN contributing less to growth, the company is relying on operational discipline, cost controls, and supply chain optimization to maintain adjusted operating margin expansion despite mixed revenue trends.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will closely monitor (1) adoption rates and operational capacity for new product launches like FARAPULSE and expanded indications for WATCHMAN, (2) tangible improvements in urology sales execution and product pipeline progress, and (3) the integration and performance impact of upcoming M&A activities, notably the anticipated closing of the Penumbra acquisition. These milestones will be key indicators of Boston Scientific’s ability to regain momentum in growth and profitability.

Boston Scientific currently trades at $64.79, up from $59.49 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.